London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... a line under the vast majority of Zantac litigation, removing a clear ...

Shares of GSK plc were losing more than 4 percent on the London Stock Exchange as well as in the early morning trading on the NYSE after the British drug maker reported Wednesday sharply lower profit ...

Reported earnings turn negative Expectedly, the company's reported earnings were affected by the payout for Zantac related settlements. I had last written about GSK earlier this month, following ...

Earlier this month, GSK reached a $2.2 billion settlement to end most of its lawsuits in the US, claiming that its discontinued version of the heartburn drug Zantac caused cancer. It took a £1.8 ...

GSK (LSE: GSK) shares fell 3.4% to 1,401p ... $2.2bn settlement in the US to end most of its lawsuits in relation to Zantac, the heartburn drug that allegedly caused cancer. This issue has long ...

GSK shares fell on Wednesday after the ... s agreement to settle the vast majority of US lawsuits against its Zantac drug without admitting liability. Stripping out the litigation costs, GSK ...

(Alliance News) - GSK PLC on Wednesday backed its full-year ... as its bottom line was hit by a GBP1.8 billion charge in relation to a Zantac court settlement. Core operating profit, however ...

GSK said total sales fell by two per cent in the third quarter Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and ...

Arexvy has been affected by an unexpected recommendation from US officials to restrict access to adults aged 75 or over and more at risk ... she said. Zantac Litigation Walmsley has bet on GSK’s ...

Excluding its Covid-19 solutions and at constant exchange rates, GSK still expects to deliver top-line growth of 7-9%. With the uncertainty caused by recent Zantac litigation now over, Shore ...

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance ... recommending routine use of RSV vaccines in all adults 75 and above, instead of its previous recommendation for all adults ...